Syndax Pharmaceuticals INC Form 4 insider transactions

Michael Metzger, CEO of Syndax Pharmaceuticals, reports acquisition of common stock and stock options.

Director Dennis Podlesak acquired 50,000 shares of Syndax Pharmaceuticals common stock on February 5, 2025, as part of a restricted stock unit award.

Director Aleksandra Rizo acquired 25,000 shares of Syndax Pharmaceuticals common stock on February 5, 2025, through an award of restricted stock units.

Director William Meury reports acquisition of 25,000 shares of Syndax Pharmaceuticals and disposal of 90,000 shares.

Director Keith Katkin reports acquisition and disposal of Syndax Pharmaceuticals stock.

Director Jennifer Jarrett reports the acquisition of 25,000 shares of Syndax Pharmaceuticals stock through a restricted stock unit award and the disposal of 90,000 shares.

Director Martin H. Huber Jr. of Syndax Pharmaceuticals Inc. reports the acquisition of 25,000 restricted stock units on February 5, 2025.

Director Pierre Legault reports the acquisition of 25,000 shares of Syndax Pharmaceuticals stock and the disposal of 90,000 shares.

Keith A. Goldan, CFO of Syndax Pharmaceuticals, recently purchased 1,250 shares of common stock at a price of $20.0298 per share.

Director Aleksandra Rizo acquired 35,000 stock options in Syndax Pharmaceuticals on May 15, 2024.